- Home
- CLSD vs CATO Comparison
CLSD vs CATO Comparison
Compare CLSD & CATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSD
- CATO
- Stock Information
- Founded
- CLSD 2011
- CATO 1946
- Country
- CLSD United States
- CATO United States
- Employees
- CLSD N/A
- CATO N/A
- Industry
- CLSD Biotechnology: Pharmaceutical Preparations
- CATO Clothing/Shoe/Accessory Stores
- Sector
- CLSD Health Care
- CATO Consumer Discretionary
- Exchange
- CLSD Nasdaq
- CATO Nasdaq
- Market Cap
- CLSD 68.6M
- CATO 63.9M
- IPO Year
- CLSD 2016
- CATO N/A
- Fundamental
- Price
- CLSD $0.94
- CATO $2.70
- Analyst Decision
- CLSD Strong Buy
- CATO
- Analyst Count
- CLSD 5
- CATO 0
- Target Price
- CLSD $5.20
- CATO N/A
- AVG Volume (30 Days)
- CLSD 103.8K
- CATO 43.8K
- Earning Date
- CLSD 05-14-2025
- CATO 05-27-2025
- Dividend Yield
- CLSD N/A
- CATO 12.78%
- EPS Growth
- CLSD N/A
- CATO N/A
- EPS
- CLSD N/A
- CATO N/A
- Revenue
- CLSD $1,664,000.00
- CATO $649,806,000.00
- Revenue This Year
- CLSD N/A
- CATO N/A
- Revenue Next Year
- CLSD $675.15
- CATO N/A
- P/E Ratio
- CLSD N/A
- CATO N/A
- Revenue Growth
- CLSD N/A
- CATO N/A
- 52 Week Low
- CLSD $0.70
- CATO $2.19
- 52 Week High
- CLSD $1.65
- CATO $6.70
- Technical
- Relative Strength Index (RSI)
- CLSD 62.45
- CATO 55.10
- Support Level
- CLSD $0.81
- CATO $2.20
- Resistance Level
- CLSD $0.90
- CATO $2.81
- Average True Range (ATR)
- CLSD 0.05
- CATO 0.17
- MACD
- CLSD 0.01
- CATO 0.07
- Stochastic Oscillator
- CLSD 99.85
- CATO 81.15
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories primarily in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.